Arcing toward AI
British partnership using AI for early drug discovery
LifeArc announced in January it is tapping into AI capabilities at the University of Cambridge’s Milner Therapeutics Institute through a partnership aimed at identifying and validating new targets for cancer immunotherapy and respiratory disease early in the drug discovery process.
Catherine Kettleborough, head of biology and associate director for medical research charity LifeArc, told BioCentury the primary aim of the project is to determine where in the drug development process AI and machine learning technologies can have the greatest impact to improve end-target validation and make it more efficient. The partnership will move them into a space currently occupied by U.K. companies like BenevolentAI and AI VIVO Ltd., which have machine learning-based drug discovery platforms but have yet to move into in vitro or in vivo validation...